Medicus Pharma Ltd. (NASDAQ: MDCX) announced results from an expanded analysis of its Phase 2 SKNJCT-003 study evaluating a doxorubicin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE